Summary Bone Growth Stimulators (“BGS”) comprise the largest segment of revenue and more than half of profits, while also driving growth at Orthofix. Other segments are lower margin, commodity businesses and/or showing declines and pricing pressure. BGS is absolutely the only reason to own Orthofix. October 2016: FDA is actively moving to “down classify” BGS…

Read More